[Epidermal growth factor for enhancing DNA synthesis of hepatocytes and its protecting effect on animals with liver injury].
Epidermal growth factor (EGF) was purified chromatographically from mice submaxillary glands, and its activity and electrophoretic pureness were identified. The effect of EGF, glucagon-insulin (G-Ins) and EGF-glucagon-insulin mixture(EGF-G-Ins) on stimulation of DNA synthesis in primary cultures of rat hepatocytes and their protective effect on mice with liver injury were investigated. The results showed that G-Ins had significant effect on DNA synthesis in primary hepatocyte culture; EGF showed more significant effect compared with G-Ins; and EGF-G-Ins had the best effect. EGF-G-Ins could increase the survival rate and improve the repair of injured hepatocytes in mice treated with D-galactosamine. Although EGF and G-Ins could reduce the degree of hepatic injury, they did not elevate the survival rate. The present study provided some information on clinical therapy with EGF-G-Ins in patients with fulminant hepatic failure.
Huang
H L
HL
Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing.
D000818:Animals; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy*; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects*; D004815:Epidermal Growth Factor / Q000494:pharmacology* / Q000627:therapeutic use; D005688:Galactosamine; D005934:Glucagon / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D008099:Liver / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D051381:Rats
D007328:Insulin; D004815:Epidermal Growth Factor; D005688:Galactosamine; D004247:DNA; D005934:Glucagon